Much-Hyped Renal Denervation Devices Could Help Diabetics, Too

Source: Fierce Medical Devices, Damian Garde (10/5/12)

"Renal denervation devices, designed to treat hypertension, are already tabbed for big sales in that sphere--$2.8 billion by 2020, analysts say. Now, new research suggests the nerve-deadening procedure could benefit diabetics, an even larger patient population."

Fierce Medical Devices, Damian Garde

Renal denervation devices, designed to treat hypertension, are already tabbed for big sales in that sphere--$2.8 billion by 2020, analysts say. Now, new research suggests the nerve-deadening procedure could benefit diabetics, an even larger patient population.

As MedPage Today reports, scientists at the European Association for the Study of Diabetes meeting in Berlin said renal denervation has shown promise to improve insulin and glucose levels in diabetics in small, early trials. The treatment also reduced levels in C-peptide, a marker of beta-cell function, according to Felix Mahfoud of Saarland University in Germany. . .View Full Article

Cleantech Co. Advances Antimicrobial Wound Care Breakthrough
Source: Streetwise Reports (10/17/2025)

Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization."

Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Source: Streetwise Reports (10/02/2025)

Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Source: Dr. Douglas Loe (08/13/2025)

Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating.

Cleantech/Life Sciences Co. Advances Products in Q2/25
Source: Richard Ryan (08/04/2025)

BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report.

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis (07/14/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report.